ArticleScientific reports2025
Replacing protruding domains of MrNV virus-like particles with sialic acid binding domains enhances binding to SARS-CoV-2 susceptible cells and reduces pseudovirus infection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The SARS-CoV-2 virus continues to pose a public health threat due to its ability to rapidly mutate into multiple variants via mutation in its spike (S1/2) proteins. These mutations can lead to viral variants capable of escaping antibody neutralization. The interaction between the SARS-CoV-2 spike protein and the host ACE2 receptor is influenced by carbohydrate-mediated mechanisms, as the spike is heavily glycosylated with terminal sialic acids, making these sugar moieties attractive targets for therapeutic intervention. We aimed to study the complete replacement of their protrusion domains of Macrobrachium rosenbergii nodavirus capsid protein with the larger ligands in the form of carbohydrate-recognition domain derived from a terminal sialic acid-binding lectin (tsCRD). We produced chimeric virus-like particles MrNV-VLPs to display the tsCRD peptide sequence of the Sambucus Nigra Agglutinin (SNA-I). The tsCRD-MrNV-VLPs maintained their icosahedral structure and increased binding and uptake into ACE2-overexpressing cells. Additionally, these particles exhibited significant blocking capability against various SARS-CoV-2 pseudo-virus variants such as Wuhan, Delta, and Omicron. Our results demonstrated that tsCRD-MrNV-VLPs have the potential to be developed into an effective agent to block and reduce SARS-CoV-2 infection in susceptible cells and present the potential of these VLPs for protective applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.